IRIS
ROSSI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.255
AS - Asia 627
EU - Europa 600
Continente sconosciuto - Info sul continente non disponibili 18
AF - Africa 5
SA - Sud America 5
OC - Oceania 4
Totale 2.514
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.218
SG - Singapore 390
IT - Italia 355
CN - Cina 168
SE - Svezia 96
GB - Regno Unito 54
IN - India 36
CA - Canada 34
DE - Germania 29
EU - Europa 18
NL - Olanda 16
RO - Romania 13
FR - Francia 8
HK - Hong Kong 8
ES - Italia 7
UA - Ucraina 6
FI - Finlandia 5
IR - Iran 5
JP - Giappone 5
TW - Taiwan 5
CL - Cile 4
CZ - Repubblica Ceca 4
PK - Pakistan 4
AU - Australia 3
CH - Svizzera 3
EG - Egitto 3
DZ - Algeria 2
MX - Messico 2
MY - Malesia 2
RU - Federazione Russa 2
BD - Bangladesh 1
BR - Brasile 1
GR - Grecia 1
GT - Guatemala 1
KR - Corea 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SA - Arabia Saudita 1
TR - Turchia 1
Totale 2.514
Salva come PNG Salva come JPEG
Città #
Chandler 230
Singapore 152
Santa Clara 122
Milan 108
Lawrence 106
Princeton 106
Wilmington 58
Catanzaro 47
Chicago 45
London 43
Des Moines 40
Ashburn 37
Beijing 35
Ottawa 28
Guangzhou 13
Redwood City 13
Shanghai 11
Boardman 10
Redmond 10
Rome 10
Pune 9
Hong Kong 8
Los Angeles 7
Cosenza 6
Horia 6
Jiaxing 6
Leawood 6
Mountain View 6
Naples 6
Timisoara 6
Ahmedabad 5
Augusta 5
Helsinki 5
Kulgam 5
Reggio Calabria 5
San Nicola Manfredi 5
Berlin 4
Hanover 4
Norwalk 4
San Jose 4
Settingiano 4
Taoyuan District 4
Utrecht 4
Zhengzhou 4
Andover 3
Barcelona 3
Bari 3
Castrovillari 3
Cetraro 3
Clifton 3
Council Bluffs 3
Dongyang 3
Edmonton 3
Ferrara 3
Hefei 3
Kumar 3
Masera 3
Nanjing 3
New York 3
Olomouc 3
Paris 3
Rochester 3
San Antonio 3
Santo Stefano di Rogliano 3
Shenzhen 3
Wuxi 3
6th of October City 2
Apo 2
Benevento 2
Bologna 2
Bosio 2
Brescia 2
Brugnera 2
Ceglie Del Campo 2
Delhi 2
Fayetteville 2
Frankfurt am Main 2
Grottaglie 2
Hebei 2
Karachi 2
Madrid 2
Mexico City 2
Milton Keynes 2
Mumbai 2
Munich 2
Neath 2
Parma 2
Piscataway 2
Portici 2
Quanzhou 2
Saint-Fons 2
San Francisco 2
Santiago 2
Spezzano della Sila 2
Tauberbischofsheim 2
The Dalles 2
Tlemcen 2
Ulm 2
Washington 2
Xi'an 2
Totale 1.486
Salva come PNG Salva come JPEG
Nome #
A Comprehensive Safety Evaluation of Trabectedin and Drug-Drug Interactions of Trabectedin-Based Combinations 111
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 73
miR-22 suppresses DNA ligase III addiction in multiple myeloma 73
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 60
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 47
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 47
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 46
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 45
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 43
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 42
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 41
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 41
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 39
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 36
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study 35
Mir-221/222 are promising targets for innovative anticancer therapy 35
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 34
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 34
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 33
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 32
Daunorubicina liposomiale in ematologia 31
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice 31
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 30
CD7+ acute leukemia switching from a lymphoid to a myeloid phenotype 30
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 30
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 30
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 30
Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia 29
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 28
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 28
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 28
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 28
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 27
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 27
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 27
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 26
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy 25
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 25
Mycosis fungoides and gastric t-cell lymphoma: A case report 25
Mouse models of Multiple Myeloma: technologic platforms and perspectives 24
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 24
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 23
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 23
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 23
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. 23
Role of Nucleophosmin in embryionic development and tumorigenesis 23
MicroRNAs in multiple myeloma and related bone disease 23
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 22
The non-coding RNA landscape of plasma cell dyscrasias 22
Molecular Targets for the Treatment of Multiple Myeloma 22
Immunologic microenvironment and personalized treatment in multiple myeloma 21
Enumeration of IL-10-positive B cells from peripheral blood of Chronic Lymphocytic Leukemia patients 21
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 21
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma 19
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 19
Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. 19
Dendritic cells have the option to express IDO-mediated suppression or not 19
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile 19
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 18
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 18
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 18
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. 17
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 17
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor 16
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 16
MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma 16
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 15
Translational Studies on the Bone Marrow Microenvironment in Multiple Myeloma: Experimental Models and Emerging Therapeutical Strategies 15
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 15
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 14
Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability 14
Selective targeting of IRF4 by sytnthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 14
Non-Coding RNAs in multiple myeloma bone disease pathophysiology 14
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells 13
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 13
New Approaches to Predict Outcome and Personalize Therapy in Multiple Myeloma: from microRNAs to Integrated Genomics 13
Multiple myeloma-related bone disease: state-of-art and future treatments 13
Targeting oncogenic miR-17-92 primary transcripts by LNA gapmeRs in multiple myeloma: Molecular findings and therapeutic potential 13
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 13
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 13
MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches 12
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 12
Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease 12
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 12
Emerging Role of MicroRNAs in the Pathophysiology of Immune System 12
Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo 12
Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and adaptive Immunity 12
Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management? 12
Non Homologous End Joining As a New Prognostic Factor and Potential Target in Multiple Myeloma 12
miR-29b is involved in the differentiation of dendritic cells and osteoclasts from human monocytes 12
Hedgehog pathway in myeloma pathobiology and as potential therapeutic target 12
Multiple Myeloma Cells downregulatemiR-29b in dendritic cells to promote a tumor permissive inflammatory microenvironment and immune escape 12
Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor 12
Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety 12
Primary large B-cell lymphoma involving the cerebellopontine angle mimic acoustic schwannoma: Role of MR Spectroscopy in differential diagnosis. A case report 11
Plasmacytoid dendritic cells: a role after allogeneic stem cell transplantation? 11
Role of homologous end joining in multiple myeloma genetic instability and as a potential prognostic marker 11
miR-29b targets HDAC4 and mediates activity of HDAC inhibitors in multiple myeloma cells 11
Targeting oncogenic miR-17-92 primary transcripts by LNA gapmeRs in multiple myeloma: Molecular findings and therapeutic potential 11
Phosphoproteomic analysis of miR-21 modulation in Th17 cells: Potential implications for multiple myeloma bone disease therapy 11
Totale 2.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.710
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.710
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202037 0 0 0 0 0 0 0 0 0 0 11 26
2020/2021200 4 1 8 10 23 12 7 20 36 35 39 5
2021/2022319 9 4 4 72 36 17 10 58 25 30 48 6
2022/2023723 223 37 33 46 69 54 4 49 103 38 51 16
2023/2024325 74 44 23 18 26 87 8 7 2 9 13 14
2024/2025969 190 93 67 69 96 167 30 40 142 69 6 0
Totale 2.641